Business Context and Reporting Period
This Form 8-K, dated June 25, 2026, reports on Bleichroeder Acquisition Corp. II (BBCQ), a Cayman Islands exempted company and emerging growth company. The filing details the entry into Amendment No. 2 to the previously announced Agreement and Plan of Merger with Pasqal Holding SAS (Pasqal), a French quantum computing company. The transaction, referred to as the "Business Combination," was originally announced on February 28, 2026, and amended on May 26, 2026.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Bleichroeder or Pasqal. This report focuses exclusively on the legal and structural amendments to the merger agreement. The filing notes that Pasqal has a limited operating history and that the combined company may require additional future financing.
Material Changes Versus Prior Period
The primary material change reported is the execution of Amendment No. 2 to the Business Combination Agreement. Key revisions include:
- Board Composition: The initial board of the Surviving Corporation will consist of nine directors. Five must be French or European citizens and non-U.S. residents. Six directors will be jointly designated by Parent and Pasqal, with the remainder being independent directors under Nasdaq rules.
- Equity Incentive Plan (LTIP): The amendment removes a provision that would have granted the CEO and Chairman of Pasqal's supervisory board awards of up to 1% of the Surviving Corporation's shares (on a fully-diluted basis) in addition to the existing 10% allocation for the LTIP.
Guidance, Outlook, Risks, and Contingencies
Outlook and Process: The business combination is subject to shareholder approval by Bleichroeder shareholders and regulatory approvals. A registration statement on Form F-4 has been filed with the SEC, which will serve as the proxy statement/prospectus. The filing includes extensive forward-looking statements regarding the potential benefits of the combination and Pasqal's growth strategy.
Risks and Contingencies: The filing highlights significant risks, including:
- Failure to consummate the transaction due to lack of shareholder or regulatory approval.
- Insufficient cash remaining after shareholder redemptions to execute business plans.
- Pasqal's reliance on emerging quantum technology, which faces technical challenges and uncertain commercialization.
- Concentration of Pasqal's revenue in contracts with government or state-funded entities.
- Disruption of Pasqal's operations and potential inability to retain key employees.
- Challenges in achieving dual listing on Euronext N.V. Paris and maintaining Nasdaq listing.
Important Facts for Investor Verification
- Verify the final terms of the Long-Term Incentive Plan (LTIP) and confirm the removal of the additional 1% equity award for Pasqal executives.
- Review the Form F-4 Registration Statement (when available) for detailed financial data on Pasqal, including revenue concentration and cash burn rates.
- Monitor the redemption rate of Bleichroeder shareholders, as high redemptions could leave the combined entity with insufficient liquidity.
- Confirm the status of regulatory approvals required for the cross-border merger between a U.S. SPAC and a French company.
- Assess the board composition to ensure compliance with the new requirement for five French/European non-U.S. resident directors.